title: Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus.
abstract: We previously reported that exogenously administered isatin, an endogenous monoamine oxidase (MAO) inhibitor, significantly increased acetylcholine (ACh) and dopamine (DA) levels in the rat striatum. Selegiline [(-)-deprenil] was developed as a MAO-B inhibitor more than 30 years ago and widely used in the treatment of Parkinson's disease. Effects of isatin or selegiline were investigated in Japanese encephalitis virus (JEV)-induced post-encephalitic parkinsonism rats by a pole test for detecting motor activity and by the determination of biogenic amine levels. Motor activity of JEV-induced rats receiving isatin (100 mg/kg per day for 1 week, i.p.) or selegiline (0.2 mg/kg per day for 1 week, i.p.) was significantly improved compared with that of untreated JEV-infected rats. Both isatin and selegiline prevented the decrease in striatal DA levels in JEV-rats. The increased turnover of DA (DOPAC/DA) induced by JEV was significantly inhibited by isatin, but not by selegiline. These results suggested that exogenously administered isatin and selegiline can improve JEV-induced parkinsonism by increasing DA concentrations in the striatum.
authors.affiliation: The Research Institute of Personalized Health Sciences, Health Sciences University of Hokkaido, 061-0293 Ishikari-Tobetsu, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Hamaue
authors.forename: M
authors.initials: M
authors.lastname: Minami
authors.forename: M
authors.initials: M
authors.lastname: Terado
authors.forename: M
authors.initials: M
authors.lastname: Hirafuji
authors.forename: T
authors.initials: T
authors.lastname: Endo
authors.forename: M
authors.initials: M
authors.lastname: Machida
authors.forename: T
authors.initials: T
authors.lastname: Hiroshige
authors.forename: A
authors.initials: A
authors.lastname: Ogata
authors.forename: K
authors.initials: K
authors.lastname: Tashiro
authors.forename: H
authors.initials: H
authors.lastname: Saito
authors.forename: S H
authors.initials: SH
authors.lastname: Parvez
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D004664:Encephalitis Virus, Japanese; D018476:Hypokinesia / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology; D007510:Isatin / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology; D051381:Rats; D012642:Selegiline / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline; D007510:Isatin; D004298:Dopamine